AU2011253424B2 - Chlorotoxin variants, conjugates, and methods for their use - Google Patents

Chlorotoxin variants, conjugates, and methods for their use Download PDF

Info

Publication number
AU2011253424B2
AU2011253424B2 AU2011253424A AU2011253424A AU2011253424B2 AU 2011253424 B2 AU2011253424 B2 AU 2011253424B2 AU 2011253424 A AU2011253424 A AU 2011253424A AU 2011253424 A AU2011253424 A AU 2011253424A AU 2011253424 B2 AU2011253424 B2 AU 2011253424B2
Authority
AU
Australia
Prior art keywords
chlorotoxin
amino acid
modified
modified chlorotoxin
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011253424A
Other languages
English (en)
Other versions
AU2011253424A1 (en
Inventor
James M. Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2011253424A1 publication Critical patent/AU2011253424A1/en
Priority to AU2013204119A priority Critical patent/AU2013204119B2/en
Application granted granted Critical
Publication of AU2011253424B2 publication Critical patent/AU2011253424B2/en
Assigned to FRED HUTCHINSON CANCER CENTER reassignment FRED HUTCHINSON CANCER CENTER Request for Assignment Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
AU2011253424A 2010-05-11 2011-02-04 Chlorotoxin variants, conjugates, and methods for their use Active AU2011253424B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204119A AU2013204119B2 (en) 2010-05-11 2013-04-12 Chlorotoxin variants, conjugates, and methods for their use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33355610P 2010-05-11 2010-05-11
US61/333,556 2010-05-11
PCT/US2011/023797 WO2011142858A2 (en) 2010-05-11 2011-02-04 Chlorotoxin variants, conjugates, and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013204119A Division AU2013204119B2 (en) 2010-05-11 2013-04-12 Chlorotoxin variants, conjugates, and methods for their use

Publications (2)

Publication Number Publication Date
AU2011253424A1 AU2011253424A1 (en) 2012-12-20
AU2011253424B2 true AU2011253424B2 (en) 2016-02-04

Family

ID=44914898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011253424A Active AU2011253424B2 (en) 2010-05-11 2011-02-04 Chlorotoxin variants, conjugates, and methods for their use

Country Status (10)

Country Link
US (2) US9944683B2 (enExample)
EP (2) EP3165533B1 (enExample)
JP (2) JP2013532126A (enExample)
KR (1) KR101972173B1 (enExample)
CN (2) CN103097403B (enExample)
AU (1) AU2011253424B2 (enExample)
CA (1) CA2799169C (enExample)
ES (2) ES2811065T3 (enExample)
IL (1) IL222930B (enExample)
WO (1) WO2011142858A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
CA2749108C (en) 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
CN102688496B (zh) * 2012-01-15 2013-12-11 河南科技大学 一种ctx介导的靶向纳米载体及纳米载药体系
RU2015126650A (ru) 2012-12-10 2017-01-12 Фред Хатчинсон Кэнсер Рисёрч Сентер Партнеры липокалина по слиянию
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
WO2015042202A1 (en) 2013-09-17 2015-03-26 Blaze Bioscience, Inc. Chlorotoxin conjugates and methods of use thereof
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CA2950299A1 (en) 2014-06-02 2015-12-10 Li-Cor, Inc. Phthalocyanine probes and uses thereof
JP2018521994A (ja) * 2015-06-26 2018-08-09 フレッド ハッチンソン キャンサー リサーチ センター 治療用ペプチドおよびそれらの使用方法
JP6966424B2 (ja) 2015-09-09 2021-11-17 フレッド ハッチンソン キャンサー リサーチ センター 軟骨ホーミングペプチド
WO2017062407A1 (en) * 2015-10-07 2017-04-13 Genentech, Inc. Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates
US20190161523A1 (en) 2016-04-12 2019-05-30 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CN110072522A (zh) * 2016-10-21 2019-07-30 美国大仁医疗有限公司 提高癌细胞对顺铂的敏感性的物质和方法
US11098104B2 (en) * 2016-11-10 2021-08-24 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
AU2017366739B2 (en) 2016-12-02 2023-11-23 Angeles Therapeutics, Inc. Synthetic immune receptors and methods of use thereof
CA3049262A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
AU2018236465A1 (en) 2017-03-16 2019-08-22 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
CA3064436A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
EP3681540A4 (en) 2017-09-15 2021-05-19 Eisai, Inc. CHLOROTOXIN AGENT AND USES THEREOF
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
CA3148682A1 (en) * 2019-12-19 2021-06-24 Alan Cohen Methods of treating vascular lesions and malformations
WO2022144560A1 (en) 2020-12-30 2022-07-07 Vascular Venture Korlátolt Felelősségű Társaság Chlorotoxin derivatives and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004105A1 (en) * 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
WO2011097533A1 (en) * 2010-02-04 2011-08-11 Transmolecular, Inc. Chlorotoxin polypeptides and conjugates and uses thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
EP0282581A4 (en) 1986-09-19 1988-11-02 Scripps Clinic Res Monoclonal paratopic molecule directed to human ganglioside gd2.
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
GB2250993B (en) 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US5314992A (en) 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
WO1993023075A1 (en) 1992-05-14 1993-11-25 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
MX9400434A (es) 1993-01-14 1994-07-29 Cancer Res Campaign Tech Potenciamiento de temozolomida en celulas de tumores humanos.
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6555652B1 (en) 1997-12-05 2003-04-29 Kyogo Itoh Tumor antigen peptide derivatives
GB9809776D0 (en) 1998-05-07 1998-07-08 Nycomed Imaging As Method
ATE279411T1 (de) * 1998-08-12 2004-10-15 Daiichi Pure Chemicals Co Ltd Fluorszierende marker
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001019405A2 (de) 1999-09-14 2001-03-22 Biomedical Apherese Systeme Gmbh Magnetische nanoteilchen mit biochemischer wirksamkeit und verfahren zu ihrer herstellung sowie ihre verwendung
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
DE10020376A1 (de) 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20020077921A1 (en) 2000-12-15 2002-06-20 Paul-David Morrison Method and apparatus for an interactive catalog
US20040180846A1 (en) 2001-03-01 2004-09-16 Ruo-Pan Huang Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
US20030021810A1 (en) 2001-06-26 2003-01-30 Sontheimer Harald W. Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
AU2003207835A1 (en) 2002-02-04 2003-09-02 Auburn University Peptides for recognition and targeting of glial cell tumors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
EP2431385A3 (en) 2002-05-31 2012-07-04 Morphotek, Inc. Combination therapy with chlorotoxin
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
WO2005053611A2 (en) 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
US20080153746A1 (en) * 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
EP1756270B1 (en) 2004-04-06 2010-03-03 Transmolecular, Inc. Diagnosis and treatment of myeloid and lymphoid cell cancers with chlorotoxin or a derivative
AU2005240190C1 (en) 2004-05-06 2012-01-19 Children's Hospital Medical Center NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
GB0422901D0 (en) 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
ES2360519T3 (es) * 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
NZ565294A (en) 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
WO2007117467A2 (en) 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
WO2007137163A2 (en) 2006-05-19 2007-11-29 Georgia Tech Research Corporation Abc transporter ligand
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
JP2010535811A (ja) 2007-08-07 2010-11-25 トランスモレキュラー， インコーポレイテッド 薬物キャリアとしてのクロロトキシン
EP2193438A4 (en) 2007-08-31 2012-01-04 Iosemantics Llc QUALITY ASSURANCE INSTRUMENTS FOR USE WITH A SOURCE CODE AND SEMANTIC MODEL
EP2211913A4 (en) 2007-10-12 2010-12-22 Transmolecular Inc SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US7904868B2 (en) 2007-10-17 2011-03-08 International Business Machines Corporation Structures including means for lateral current carrying capability improvement in semiconductor devices
US20090176274A1 (en) 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
JP2011501673A (ja) 2007-10-19 2011-01-13 アボット・ラボラトリーズ グリコシル化された哺乳動物ｎｇａｌ及びその使用
WO2009062520A1 (en) 2007-11-15 2009-05-22 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
CA2749108C (en) * 2008-01-18 2017-06-27 Visen Medical, Inc. Intramolecularly-quenched fluorescent imaging agents
US9308239B2 (en) 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8093060B2 (en) * 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
AU2009223235B2 (en) * 2008-03-14 2014-09-11 Merck Sharp & Dohme Corp. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
US8470607B2 (en) 2008-03-20 2013-06-25 Morphotek, Inc. Inhibition of angiogenesis
GB0807831D0 (en) * 2008-04-29 2008-06-04 Cambridge Entpr Ltd Agents for imaging cell death
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
JP2009300110A (ja) * 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
AR073582A1 (es) * 2008-09-12 2010-11-17 Nitto Denko Corp Agentes de produccion de imagenes de enfermedades fibroticas.conjugado. metodo
US20100098637A1 (en) * 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2011057295A2 (en) 2009-11-09 2011-05-12 University of Washington Center for Commercialization Functionalized chromophoric polymer dots and bioconjugates thereof
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
EP3299386A1 (en) 2010-08-16 2018-03-28 Pieris Pharmaceuticals GmbH Binding proteins for hepcidin
RU2015126650A (ru) 2012-12-10 2017-01-12 Фред Хатчинсон Кэнсер Рисёрч Сентер Партнеры липокалина по слиянию
EP3442555A4 (en) * 2016-04-15 2020-04-01 Blaze Bioscience, Inc. METHOD FOR TREATING BREAST CANCER
CA3021011A1 (en) * 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004105A1 (en) * 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
WO2011097533A1 (en) * 2010-02-04 2011-08-11 Transmolecular, Inc. Chlorotoxin polypeptides and conjugates and uses thereof

Also Published As

Publication number Publication date
EP3165533B1 (en) 2020-04-08
ES2811065T3 (es) 2021-03-10
EP2569330B1 (en) 2016-09-28
JP2013532126A (ja) 2013-08-15
IL222930B (en) 2019-01-31
US9944683B2 (en) 2018-04-17
WO2011142858A9 (en) 2012-03-22
CN103097403A (zh) 2013-05-08
EP2569330A2 (en) 2013-03-20
JP6553105B2 (ja) 2019-07-31
EP3165533A1 (en) 2017-05-10
US20180194818A1 (en) 2018-07-12
CA2799169A1 (en) 2011-11-17
KR20130113938A (ko) 2013-10-16
ES2601182T3 (es) 2017-02-14
CA2799169C (en) 2019-07-23
WO2011142858A2 (en) 2011-11-17
US10822381B2 (en) 2020-11-03
CN106957356B (zh) 2021-05-25
JP2017137316A (ja) 2017-08-10
CN103097403B (zh) 2017-04-19
CN106957356A (zh) 2017-07-18
IL222930A0 (en) 2012-12-31
KR101972173B1 (ko) 2019-04-24
AU2011253424A1 (en) 2012-12-20
EP2569330A4 (en) 2013-11-13
WO2011142858A3 (en) 2012-01-05
US20130195760A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
US10822381B2 (en) Chlorotoxin variants, conjugates, and methods for their use
US20230151068A1 (en) Peptide compositions and methods of use thereof for disrupting tead interactions
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
CN114478707B (zh) 一种构象锁定蜂毒肽衍生物、偶联物及其制备和用途
AU2013204119B2 (en) Chlorotoxin variants, conjugates, and methods for their use
CN111511917B (zh) 肽结合物
WO2024212817A1 (zh) 一种氯毒素类似物的多肽偶联物及其用途
CN116804049A (zh) 铁蛋白示踪多肽缀合物及其用途
WO2006060664A2 (en) Single-drug multi-ligand conjugates for targeted drug delivery
Ahmed Nanoscale modification of therapeutic peptidomimetics to improve tissue distribution and cell type targeting

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: FRED HUTCHINSON CANCER CENTER

Free format text: FORMER OWNER(S): FRED HUTCHINSON CANCER RESEARCH CENTER